ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,296.20
-0.32%
S&P ASX All Technology
4,030.80
-1.66%
Brent Oil
73.935
0.00%
US Dollar vs AUD
1.57307
0.00%
Bitcoin
95,583.32
-1.02%
Pepperstone
Advertisement
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. AN2 Therapeutics Inc (ANTX) Share Price

AN2 Therapeutics Inc

AN2 Therapeutics Inc (ANTX)

NASDAQ
1.13
0.00
(0.00%)
Closed 24 February 8:00AM
Delayed by 15 minutes
1.1399
0.0099
(0.88%)
After Hours: 9:32AM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
1.1399
Bid
0.88
Offer
1.84
Volume
342,633
1.1201 Day's Range 1.15
0.87 52 Week Range 3.88
Market Cap
34.059M
Previous Close
1.13
Open
1.13
Last Trade
300
@
1.1399
(formt)
Last Trade Time
Financial Volume
US$ 389,310
VWAP
1.1362
Average Volume (3m)
192,949
Shares Outstanding
29,878,890
Dividend Yield
-
PE Ratio
-0.53
Earnings Per Share (EPS)
-2.17
Revenue
-
Net Profit
-64.73M

About AN2 Therapeutics Inc

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NT... AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.an2therapeutics.com
Headquarters
Dover, Delaware, USA
Founded
-
AN2 Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANTX. The last closing price for AN2 Therapeutics was US$1.13. Over the last year, AN2 Therapeutics shares have traded in a share price range of US$ 0.87 to US$ 3.88.

AN2 Therapeutics currently has 29,878,890 shares in issue. The market capitalisation of AN2 Therapeutics is US$33.76 million. AN2 Therapeutics has a price to earnings ratio (PE ratio) of -0.53.

Ask ADVFN Intelligence (AI)

ANTX Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
08 January 2025
ANTX (0.00%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
08 January 2025
ANTX (0.00%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
08 January 2025
ANTX (0.00%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
24 December 2024
ANTX (0.00%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
24 December 2024
ANTX (0.00%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
24 December 2024
ANTX (0.00%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.03993.627272727271.11.20051.071442351.13534075CS
4-0.1201-9.531746031751.261.271.04991393081.13616915CS
12-0.3401-22.97972972971.481.6751.04991929491.37487362CS
260.07997.537735849061.061.6750.9753798121.19890791CS
52-2.5001-68.68406593413.643.880.874028161.6438103CS
156-15.7101-93.235014836816.8523.580.871946234.37052252CS
260-15.7101-93.235014836816.8523.580.871946234.37052252CS

ANTX - Frequently Asked Questions (FAQ)

What is the current AN2 Therapeutics share price?
The current share price of AN2 Therapeutics is US$ 1.1399
How many AN2 Therapeutics shares are in issue?
AN2 Therapeutics has 29,878,890 shares in issue
What is the market cap of AN2 Therapeutics?
The market capitalisation of AN2 Therapeutics is USD 33.76M
What is the 1 year trading range for AN2 Therapeutics share price?
AN2 Therapeutics has traded in the range of US$ 0.87 to US$ 3.88 during the past year
What is the PE ratio of AN2 Therapeutics?
The price to earnings ratio of AN2 Therapeutics is -0.53
What is the reporting currency for AN2 Therapeutics?
AN2 Therapeutics reports financial results in USD
What is the latest annual profit for AN2 Therapeutics?
The latest annual profit of AN2 Therapeutics is USD -64.73M
What is the registered address of AN2 Therapeutics?
The registered address for AN2 Therapeutics is 850 NEW BURTON ROAD, SUITE 201, KENT, DOVER, DELAWARE, 19904
What is the AN2 Therapeutics website address?
The website address for AN2 Therapeutics is www.an2therapeutics.com
Which industry sector does AN2 Therapeutics operate in?
AN2 Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MLGOMicroAlgo Inc
US$ 6.3767
(454.50%)
531.54M
BOXLBoxlight Corporation
US$ 3.1099
(51.70%)
1.84M
GDEVGDEV Inc
US$ 20.90
(46.56%)
264.44k
IVVDInvivyd Inc
US$ 1.7501
(44.64%)
37.75M
UPCUniverse Pharmaceuticals Inc
US$ 0.2003
(40.56%)
420.21M
DOYUDouYu International Holdings Ltd
US$ 7.19
(-55.31%)
1.28M
MNDRMobile health Network Solutions
US$ 0.5048
(-46.29%)
18.61M
BLUEbluebird bio Inc
US$ 4.09
(-41.90%)
5.44M
FLDFold Holdings Inc
US$ 6.95
(-37.39%)
488.54k
GCLGCL Global Holdings Ltd
US$ 3.83
(-31.48%)
635.26k
MLGOMicroAlgo Inc
US$ 6.3767
(454.50%)
531.54M
UPCUniverse Pharmaceuticals Inc
US$ 0.2003
(40.56%)
420.21M
ADTXAditxt Inc
US$ 0.0922
(-22.39%)
278.25M
NVDANVIDIA Corporation
US$ 134.43
(-4.05%)
228.14M
HOLOMicroCloud Hologram Inc
US$ 1.565
(31.51%)
190.81M

ANTX Discussion

View Posts
glenn1919 glenn1919 2 months ago
ANTX.....................https://stockcharts.com/h-sc/ui?s=ANTX&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 months ago
ANTX........................https://stockcharts.com/h-sc/ui?s=ANTX&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
ANTX NEXT WEEK WATCH
👍️0
stocksrising stocksrising 3 months ago
Open market purchase always welcomed :)..even if tiny 😜

Common Stock-CEO
11/18/2024
50,000
A
$0.9994
1,065,76
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
ANTX MINI BIO BEAST
👍️ 1
stocksrising stocksrising 3 months ago
I haven’t done much DD on this bio, but it seems they have several readouts within 6-12mos. that could propel stock higher (especially with the $$$ runway position)… as you know, any biotech is risky but I like the odds on this one and starter position is small for now…I did copy this from release that I found appealing:

Boron Chemistry Pipeline

Additional development programs are underway and focused on targets in infectious diseases and oncology with high unmet needs. The Company anticipates delivering up to three development compounds in 2025.

Global Health

In October, the Company announced that it received a second-year continuation of a research grant from the Bill & Melinda Gates Foundation to discover novel boron containing small molecules for the treatment of tuberculosis and malaria. The Company will continue its efforts to tackle global health disease through non-dilutive funding.
👍️0
eyeownu eyeownu 3 months ago
NOPE. took my looses moved them over to $EBS and made it all back. do you notice anything promising that warrants investing in this company besides the cash on hand?
👍️0
stocksrising stocksrising 3 months ago
Picked up a bit more down here at $1ish, you still in??
👍️0
Monksdream Monksdream 7 months ago
ANTX new 52 week low
👍️0
Monksdream Monksdream 7 months ago
ANTX under $3
👍️0
eyeownu eyeownu 7 months ago
looking good
👍️0
glenn1919 glenn1919 8 months ago
ANTX..............https://stockcharts.com/h-sc/ui?s=ANTX&p=W&b=5&g=0&id=p86431144783
👍️0
GO4AWILDRIDE GO4AWILDRIDE 11 months ago
FROM 3/28 NEWS:

Cash, cash equivalents, and investments of $134.5 million at December 31, 2023

GO4AWILDRIDE
👍️0
GO4AWILDRIDE GO4AWILDRIDE 11 months ago
THE FOLLOWING FROM THE 3/28 NEWS:

“AN2’s cash position remains strong as we advance our innovative boron-based pipeline. Following the recent meeting of the independent Data Safety Monitoring Board, we continue to believe in the potential of epetraborole to become an important component of the backbone therapy for NTM lung disease,” said Eric Easom, Co-Founder, President and Chief Executive Officer. “Patients enrolled in the epetraborole Phase 2/3 trial in treatment refractory lung disease caused by MAC continue to be dosed while new enrollment in the Phase 3 part of the trial remains paused. Patients in the Phase 2 trial have reached the six-month mark, and we plan to report topline results this summer. Analysis of the baseline patient demographics from the trial show a highly complex and refractory patient population, which we plan to discuss with the FDA in the coming months.”

GO4AWILDRIDE
👍️0
GO4AWILDRIDE GO4AWILDRIDE 11 months ago
Monksdream

Did you read the 3/28 news from the compay?

Seems like the market is looking to chase the price up.

GLTU

GO4AWILDRIDE
👍️0
GO4AWILDRIDE GO4AWILDRIDE 11 months ago
Monksdream

Seems like a nice rebound is starting to occur.

GLTU

GO4AWILDRIDE
👍️0
Monksdream Monksdream 12 months ago
ANTX new 52 week low
👍️0
Monksdream Monksdream 12 months ago
ANTX new 52 week low
👍️0
Monksdream Monksdream 1 year ago
ANTX new 52 week low
👍️0

Your Recent History

NASDAQ
ANTX
AN2 Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads